The sale realized $7.0 million based on a weighted average execution price.
The transaction represents a 47% reduction in Mayer direct equity holdings.
Mayer maintains a direct position of 33,076 shares following the disposition.
Jessica L. Mayer, chief legal officer of Cardinal Health, Inc. (NYSE:CAH), sold 29,436 shares of common stock at $236.19 per share on August 18, according to an SEC Form 4 filing.
| Metric | Value |
|---|---|
| Shares sold | 29,436 |
| Transaction value | ~$7.0 million |
| Post-transaction shares (directly held) | 33,076 |
| Post-transaction value | $7.77 million |
Transaction value based on SEC Form 4 weighted average sale price ($236.19); post-transaction value based on the August 18 market close ($234.98).
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-19) | $234.85 |
| Market Capitalization | $55.0 billion |
| Revenue (TTM) | $254.2 billion |
| Net Income (TTM) | $1.7 billion |
Cardinal Health is one of the largest healthcare services and products companies globally. The company maintains a competitive position through its integrated distribution network, broad customer relationships, and diversified service offerings across pharmaceutical and medical segments. Cardinal Health's scale and operational infrastructure enable it to serve as a critical intermediary within the healthcare supply chain, supporting healthcare providers and patients across multiple geographies and care settings.
Mayer wasn't alone on Aug. 18. CFO Aaron Alt sold 42,000 shares the same day, and CIO Michelle Greene sold 11,650, for example, and all three had performance share units settle on Aug. 15. Though the filing seems routine, Mayer's seat is what makes the filing worth reading. Analysts spent much of the Aug. 11 earnings call pressing management on 340B, the federal program requiring discounted drug prices for hospitals that serve low-income patients, plus Medicare price setting under the Inflation Reduction Act. CEO Jason Hollar was blunt about it, saying "we don't see our role changing and we don't believe our compensation should change."
Fiscal 2027 pharma revenue growth of 3% to 5% already builds in IRA pricing pressure, and Alt said the company is assuming the same percentage impact it just absorbed, roughly 500 basis points off segment revenue in the fourth quarter, offset almost exactly by GLP-1 volume. The January rate changes are the first live test of whether that offset holds.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.